On January 30, 2026, Boeing filed its 2025 10-K. $89.4 billion in revenue. $4.3 billion in operating income. The stock was sitting at $220 — about 13% off its 52-week high of $254, still dragging residue from a year most investors would rather forget.
That gap is the article.
Boeing just added another defense contract under the PAC-3 missile defense program to a ledger that already includes a ViaSat-3 spacecraft delivery and a string of government awards that don’t make headlines the way door plugs do. The commercial disaster narrative is loud. The defense revenue stream is not. The defense side of this business is doing something the market keeps discounting: it’s producing.
The fiscal year 2027 defense budget proposal sits at $1.5 trillion. It is the largest proposed defense outlay in U.S. history. Boeing doesn’t capture all of it — nobody does — but it is structurally positioned inside the missile defense, rotorcraft, and satellite systems lines that tend to be the last items cut and the first items expanded during geopolitical escalation cycles.
3.3%, 4.0%, 4.8%
Capex-to-revenue from the 2025 10-K: 3.3%. R&D: 4.0%. Operating margin: 4.8%.
Drop those three together and don’t rush past them.
The 3.3% capex ratio is low for a manufacturer of Boeing’s complexity. It reads like a company not investing in itself. But the capex is going toward factory retooling in Everett and Renton, production line stabilization for the 737 MAX and 787 — maintenance capex with a modernization edge. The R&D figure carries more weight: $3.6 billion in a year when production was still lurching suggests the engineering pipeline isn’t frozen.
The 4.8% operating margin is the number to unpack. Boeing ran north of 10% operating margins before the MAX crisis and the pandemic compressed everything simultaneously. At 4.8%, the company is operating at roughly half its pre-crisis efficiency. If that margin recovers to even 7% — a reasonable mid-cycle assumption given defense contract flow and commercial delivery normalization — operating income on $89.4 billion in revenue would be approximately $6.3 billion, nearly 47% above current levels. A 10% move in either direction from 4.8% produces a $430 million swing in operating income. That’s the difference between a story about recovery and a story about stagnation.
The PAC-3 contract isn’t just a revenue event. It’s a margin event. Defense contracts in the missile defense segment carry higher and more predictable margins than commercial aircraft manufacturing. The mix shift toward defense mechanically lifts consolidated margins without requiring Boeing to fix everything broken in Renton simultaneously.
The Ceasefire Variable Nobody Has Priced Cleanly
Two weeks ago, the U.S. and Iran announced a ceasefire. BA barely moved.
A sustained de-escalation with Iran doesn’t kill the PAC-3 contract or the 2027 budget proposal — those are baked into appropriations cycles that move on two- to five-year timelines, not news cycles. A prolonged ceasefire introduces uncertainty into the urgency premium embedded in missile defense procurement. If fiscal 2027 budget negotiations begin in an environment of apparent geopolitical calm, there is a real probability that missile defense line items face reallocation pressure toward readiness and conventional forces.
PAC-3 is a NATO-linked program with allied cost-sharing, not purely a bilateral Iran-response system. If the ceasefire holds past 90 days and extends into budget reconciliation season, watch how Boeing’s defense order backlog guidance shifts in Q1 2026 earnings commentary. That’s the signal.
The bull case holds because the $1.5 trillion proposal isn’t built around Iran specifically. It’s built around China, hypersonic defense gaps, and the post-Ukraine reassessment of Western munitions stockpiles. Those drivers don’t dissolve in a two-week ceasefire. Any sustained peace dividend narrative — even a politically motivated one — creates near-term noise in defense budget optics. It does not rewrite the structural demand curve.
Lockheed Martin and RTX are the obvious sector comparisons. Both have benefited from the same budget tailwind with less operational turbulence. LMT runs a cleaner operational profile; RTX’s Pratt & Whitney division has its own engine inspection headaches. Boeing’s difference: the commercial recovery, if it materializes, creates an earnings acceleration that pure-play defense contractors structurally can’t offer. The dual exposure is the risk and the asymmetry simultaneously. At $220, you’re buying the defense floor with a commercial call option attached. The volatility in the 52-week range of $152 to $254 per market data suggests the market keeps repricing the commercial drag without updating the defense credit.
Boeing at 4.8% operating margin is a company being valued on its worst recent self. The defense contract flow — PAC-3, ViaSat-3, and whatever sits in classified undisclosed awards — is building a revenue base that doesn’t depend on the 737 MAX production rate hitting 50 per month to justify the stock. Revenue at $89.4 billion, with margin mean-reversion even partially in play, produces a very different earnings number than what the last two years trained investors to expect.
The stock isn’t cheap in any classic sense. It’s a recovery trade with a defense backstop. Whether $220 is the right price depends almost entirely on how quickly the 4.8% margin moves. The weakest assumption in this thesis is that margin recovery reaches 7% in 18 months — plausible given the defense contract mix and production normalization, not guaranteed. If it doesn’t move for another two years, the thesis stalls. If it does move, you’re looking at a materially different earnings picture than what the current price reflects. The commercial drag is reflected in the stock. The defense margin expansion is not.
Wall Street spent three years treating Boeing like a commercial airline company that happened to build missiles, and now they’re shocked the missile business is the part that’s actually working.